Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 22

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 22
---
an update on progression free and overall survival in our Phase 1 trial of MTX110 in rGBM, also known as the MAGIC-G1 study. At that
time, patients 1 and 2 had deceased, with overall survival since the start of treatment of 12 months and 13 months, respectively. Patients
3 and 4 remained in post-study follow-up. Patient 3 had progression free survival of six months and overall survival of 13 months since
start of treatment. Patient 4 has not yet had confirmed progression and therefore had progression free and overall survival of 12 months
since start of treatment.

The Phase 1 study is an open-label,
dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced
delivery, or CED, via implanted refillable pump and catheter.

| 9 |

Our Corporate Information

Our
principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our
principal executive office is +44 29 20480 180. Our corporate website is located at www.biodexahpharma.com. Information contained on our
website is not part of, or incorporated in, this prospectus. Our authorized representative in the United States is Donald J. Puglisi of
Puglisi and Associates. Our agent for service in the United States is Donald J. Puglisi of Puglisi and Associates, located at 850 Library
Avenue, Suite 204, Newark, Delaware 19711. Our Depositary Shares are traded on the NASDAQ Capital Market under the symbol “BDRX.”

Implications of Being a Foreign Private Issuer

We are incorporated as a public
limited company in England and Wales, are we are deemed to be a “foreign private issuer” for the purposes of the reporting
rules under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In our capacity as a foreign private issuer, we are
exempt from certain rules under the Exchange Act that would otherwise apply if we were a company incorporated in the United States, including:

| · | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted